IP Library › Granted Patent US 11,622,547
Granted Patent B2
US 11,622,547 · App. 16/894,302 · Granted Apr 11, 2023

Genetically modified mouse that expresses human albumin

Inventors: Qing Fang (Chappaqua, NY); Chia-Jen Siao (New York, NY); Dan Chalothorn (New York, NY); KehDih Lai (Yardley, PA); Leah Sabin (Goldens Bridge, NY); Rachel Sattler (New York, NY); Brian Zambrowicz (Sleepy Hollow, NY); Lori Morton (Chappaqua, NY)
Assignee: Regeneran Pharmaceuticals, Inc.
A01K67/0278A61K49/0008C07K14/76C12N15/8509A01K2207/15A01K2227/105A01K2267/03C12N2015/8527
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,622,547
App. No.
16/894,302
Granted
Apr 11, 2023
Kind
B2
Abstract

Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized albumin (ALB) locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized albumin locus express a human albumin protein or a chimeric albumin protein, fragments of which are from human albumin. Methods are provided for using such non-human animals comprising a humanized albumin locus to assess in vivo efficacy of human-albumin-targeting reagents such as nuclease agents designed to target human albumin.

Claims (26)

1. A genetically modified mouse whose genome comprises a humanized albumin gene in which the region from the start codon to the stop codon of an endogenous albumin gene is replaced with a human nucleic acid sequence encoding human albumin and a human albumin signal peptide,

wherein the human nucleic acid sequence is operably linked to an endogenous albumin promoter and comprises the region from the start codon to the stop codon of a human albumin gene, and

wherein the mouse functionally expresses human albumin and has a serum level of human albumin that is at least as high as the serum level of mouse albumin in a wild type mouse.

2. The genetically modified mouse of claim 1 , wherein the humanized albumin gene comprises a human albumin 3′ untranslated region.

3. The genetically modified mouse of claim 1 , wherein the humanized albumin gene comprises the nucleic acid sequence of SEQ ID NO: 17, 18, or 35 or encodes the protein of SEQ ID NO: 5.

4. The genetically modified mouse of claim 1 , wherein the humanized albumin gene further comprises a selection cassette.

5. The genetically modified mouse of claim 1 , wherein the mouse is homozygous for the humanized albumin gene.

6. The genetically modified mouse of claim 1 , wherein the mouse is heterozygous for the humanized albumin gene.

7. The genetically modified mouse of claim 1 , wherein the mouse comprises serum albumin levels of at least about 10 mg/mL.

8. The genetically modified mouse of claim 1 , wherein the mouse further comprises an inactivated factor 9 (F9) gene.

9. A cell isolated from the genetically modified mouse of claim 1 .

10. A genetically modified mouse embryonic stem (ES) cell whose genome comprises a humanized albumin gene in which the region from the start codon to the stop codon of an endogenous albumin gene is replaced with a human nucleic acid sequence encoding human albumin and a human albumin signal peptide,

wherein the human nucleic acid sequence is operably linked to an endogenous albumin promoter and comprises the region from the start codon to the stop codon of a human albumin gene, and

wherein a mouse derived from the mouse ES cell is capable of functionally expressing human albumin and having a serum level of human albumin that is at least as high as the serum level of mouse albumin in a wild-type mouse.

11. A targeting vector for generating a genetically modified mouse whose genome comprises a humanized albumin gene, wherein the vector:

comprises a human nucleic acid sequence encoding human albumin and a human albumin signal peptide flanked by homology arms that target a mouse albumin gene, and

is capable of generating a genetically modified mouse whose genome comprises a humanized albumin gene in which the region from the start codon to the stop codon of an endogenous albumin gene is replaced with the human nucleic acid sequence,

wherein the human nucleic acid sequence is operably linked to an endogenous albumin promoter in the humanized albumin gene and comprises the region from the start codon to the stop codon of a human albumin gene, and

wherein the mouse is capable of functionally expressing human albumin and having a serum level of human albumin that is at least as high as the serum level of mouse albumin in a wild-type mouse.

12. A method of making a genetically modified mouse that expresses human albumin, the method comprising:

(a) obtaining a genetically modified mouse embryonic stem (ES) cell whose genome comprises a humanized albumin gene;

(b) injecting the mouse ES cell into a mouse embryo;

(c) transplanting the mouse embryo into a recipient female; and

(d) obtaining a genetically modified mouse from the transplanted mouse embryo, wherein the mouse has a genome comprising the humanized albumin gene in which the region from the start codon to the stop codon of an endogenous albumin gene is replaced with a human nucleic acid sequence encoding human albumin and a human albumin signal peptide,

wherein the human nucleic acid sequence is operably linked to an endogenous albumin promoter and comprises the region from the start codon to the stop codon of a human albumin gene, and

wherein the mouse functionally expresses human albumin and has a serum level of human albumin that is at least as high as the serum level of mouse albumin in a wild-type mouse.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF INVENTOR KEHDIH LAI PREVIOUSLY RECORDED ON REEL 058928 FRAME 0541. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Feb 15, 2022
From: FANG, QING; SIAO, CHIA-JEN; CHALOTHORN, DAN; LAI, KEHDIH; SABIN, LEAH; SATTLER, RACHEL; ZAMBROWICZ, BRIAN; MORTON, LORI
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 059110/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2022
From: FANG, QING; SIAO, CHIA-JEN; CHALOTHORN, DAN; LAI, KENDIH; SABIN, LEAH; SATTLER, RACHEL; ZAMBROWICZ, BRIAN; MORTON, LORI
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 058928/0541 →
Continuity (3)
Provisional Application 62916666 · Oct 17, 2019
Provisional Application 62858589 · Jun 7, 2019
Related Publication 20200383304A1 · Dec 10, 2020
Cited By (1)
US 12,317,874